About

About EMIT Imaging EMIT Imaging is the leading manufacturer of Cryo-Fluorescence Tomography (CFT) systems and provider of CFT fee-for-service research. CFT was created to better visualize drug distribution and protein expression (PK/PD) in whole animals at high resolution and sensitivity. Following developing a prototype system and demonstrating the vast potential of CFT, EMIT Imaging, Inc. was spun out of Invicro, LLC in 2018. EMIT designed and manufactured our flagship product, XerraTM, a fully automated preclinical imaging platform, and launched the first-generation production system in 2019. In 2023, EMIT launched CFT services to the global research community. EMIT developed CFT and Xerra to help researchers discover more from valuable preclinical experiments, complementing existing experimental paradigms and imaging workflows. CFT applications span drug discovery and delivery, oncology and immunotherapy, gene and cell therapy, neuroscience, and beyond. EMIT Imaging is driven to develop innovative CFT applications, systems, and software that meet our customers’ and collaborators’ needs. We are working on feature enhancements, workflow optimization, and data science tools that further the utility and useability of Xerra and CFT. The company is based in Baltimore, MD, and Boston, MA.